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E-mail address: benedetta.isacchi@unifi.it (B. IsaccSalvianolic acid B (SalB) represents the most characteristic constituent of Salvia miltiorrhiza Bge. with a
strong free radicals scavenger activity. This property may be useful in the treatment of some severe
chronic diseases, where there is an imbalance of reactive oxygen species formation and where
intracellular reactive oxygen and nitrogen species level can cause severe cell damage and even cell death.
In particular, SalB can protect against the oxidative stress as well as the antioxidant superoxide dismutase
and reduced activity of glutathione, important determinants of neuropathological and behavioural
consequences in neuropathic pain. This is a chronic disease defined by the WHO as an untreatable illness
because therapeutics are unsatisfactory in many cases and there is an urgent need to discover and develop
novel active drugs. In the present work, SalB has been extracted and purified with an efficient and rapid
method from the roots and rhizome ofS. miltiorrhiza Bge. It was firstly submitted to pharmacological stud-
ies using the paw-pressure test, in an animal model of neuropathic pain where a peripheral mono neurop-
athy was produced by a chronic constriction injury of the sciatic nerve. SalB was effective against
mechanical hyperalgesia when administered intraperitoneally at the dose of 100 mg/kg, 15 min after
administration. Due to the poor chemical stability and bioavailability of SalB, liposomes were developed
as drug carriers for parental administration. SalB-loaded liposomes were characterised in terms of particle
size, polydispersity index, encapsulation efficacy and morphology. According to the in vivo studies, encap-
sulation, especially into PEGylated liposomes, increased and prolonged the antihyperalgesic activity
30 min after i.p. administration and the effect was still significant at 45 min.
Thus, PEGylated formulation ameliorated the performance of drug delaying, increasing and prolonging
in time its antihyperalgesic effect.
 2011 Elsevier B.V. All rights reserved.1. Introduction
Salvianolic acid B (SalB, Fig. 1) represents the most abundant
constituent among the water-soluble compounds of roots and
rhizome of Danshen (Salvia miltiorrhiza Bge.), a medicinal plant
widely used in Asia for the treatment of a variety of diseases, in
particular cardiovascular diseases such as angina pectoris, myocar-
dial infarction and stroke (Cheng, 2006; Zhou et al., 2005; The State
Pharmacopoeia Commission of the People’s Republic of China,
2005). Ampuls of Danshen for parental administration are already
present in the Asian market and they are primarily used to treat
coronary heart disease, angina pectoris, and other heart and
stomach diseases caused by qi stagnancy and blood stasis (Wang
et al., 1997; Weng et al., 1980; Shi et al., 1981).ll rights reserved.
x: +39 055 457 3737.
hi).SalB and related constituents have strong antioxidant and free
radicals scavenger activity (higher than vitamin C) due to their
phenol hydroxyl groups (Jiang et al., 2009; Zhao et al., 2008).
Indeed, some severe chronic diseases, such as arthritis, cancer,
diabetes, cardiovascular diseases, inflammations and neurological
disorders are related to the imbalance of reactive oxygen species
(ROS) formation and elimination (Halliwell, 1996). Antioxidants
can protect against these complex diseases through scavenging
free radicals and reducing hydrogen peroxide (Shahidi and
Wanasundara, 1992). Cell damage is induced by reactive oxygen
and nitrogen species (RONS), which under normal conditions, are
cleared from cells by the action of superoxide dismutase, catalase
or glutathione, as well as antioxidant molecules but in pathological
conditions, intracellular RONS level can cause severe cell damage
and even cell death.
Neuropathic pain is a chronic disease defined by the WHO as an
untreatable illness because therapeutics are unsatisfactory in
Fig. 1. Chemical structure of SalB.
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novel active drugs (Syndrup and Jensen, 1999). Among the murine
models of neuropathic pain, the chronic constriction injury of
the sciatic nerve (CCI, Bennett and Xie, 1988) was selected for
our studies. This model is a chronic pain syndrome characterised
by allodynia (pain elicited by a non-noxious stimulus) and
hyperalgesia (increased pain response to a noxious stimulus)
which persists for a long time after the initial injury is resolved
(Woolf and Mannion, 1999).
Recently, in the CCI model of neuropathic pain, it has been
shown that the oxidative stress as well as the antioxidant
superoxide dismutase and reduced activity of glutathione are
important determinants of neuropathological and behavioural
consequences (Tan et al., 2009). For this reason SalB was selected
in this study for testing its properties in reverting hyperalgesia
and, in addition, it was investigated for its anti-inflammatory
properties using the paw-pressure test in rats (Leighton et al.,
1988). The intraperitoneal administration was chosen in order to
reproduce the parental administration of the commercial ampuls
of Danshen already existing on the Asian market (Wang et al.,
1997; Weng et al., 1980; Shi et al., 1981).
Besides the interesting biological activities of SalB, it suffers
from specific shortcomings which have limited its use as a drug,
namely an instability under UV irradiation and in aqueous
solutions, a low oral bioavailability; SalB was absorbed quickly
and eliminated rapidly from plasma after oral administration to
rats (Zhang et al., 2004). The bioavailability of SalB was found to
be extremely low in rats (Wu et al., 2006). Furthermore, studies
on rats have proven that SalB has an extensive metabolism with
a very short half-life (about 90% of the acid is eliminated within
8 h after oral administration) and a strong plasma protein binding
(between 80% and 90%) (Zhang et al., 2004; Kim et al., 2005; Yang
et al., 2008).
The use of delivery systems may help overcome both chemical
and biopharmaceutical issues and in particular liposomes have
been extensively studied for such purposes. Liposomes are very ver-
satile carriers able to formulate both hydrophilic and hydrophobic
molecules, increasing drug stability and bioavailability, widely used
for parental administration (Shoji and Nakashima, 2004). Conse-
quently, this study focussed on three aims: (i) evaluate the
anti-hyperalgesic and anti-inflammatory activities, (ii) formulate
and optimise SalB-loaded liposomes to increase its therapeutical
efficacy, and (iii) estimate the in vivo performance of liposomes in
comparison with the free drug.2. Materials and methods
2.1. Plant material and standard
S. miltiorrhiza Bge. (Lamiaceae) roots and rhizome (500 g) were
purchased by Shenzhou Medical Center, import–export s.r.l., Rome,
Italy. SalB was extracted as described in Section 2.4.1.2.2. Substances
SalB standard CRS was kindly provided by China’s National
Institute for the Control of Pharmaceutical and Biological Products
(NICPBP); (C36H30O16; MW 718.6; quality contamination >98.5%).
Ethanol was of analytical reagent grade from Riedel-de Haen
(Seelze, Germany). All solvents used were of HPLC grade; CH3CN
and MeOH were purchased from Merck (Darmstadt, Germany).
HCOOH (85%) was provided by Carlo Erba (Milan, Italy). Water was
purified by a Milli-Qplus system from Millipore (Milford, MA, USA).
Carboxymethylcellulose sodium salt (CMC) was purchased from
Fluka Chemie GmbH, Steinheim, Germany and solution NaCl 0.9%
w/v from Fresenius Kabi, Italy. Egg phosphatidylcholine
(Phospholipon 90, P90) was kindly supplied by Natterman
Phospholipids, GmbH (Cologne, Germany). Cholesterol (CHOL) was
purchased from Aldrich (Milan, Italy). PEG 2000 (18:0/18:0) was
purchased from Spectra2000 s.r.l. (Rome, Italy). All other products
andreagentswereof analytical grade: ketorolac (P99%) fromSigma,
St. Louis, USA; morphine hydrochloride (>99%) from S.A.L.A.R.
Pregabalin (>99%) was purchased from Chem Pacific, Baltimore.
2.3. Animal experiments
Male Sprague–Dawley albino rats (180–200 g) from Harlan
(S. Piero al Natisone, Italy) were used. Four rats were housed per
cage. The cages were placed in the experimental room 24 h before
the test for acclimatisation. The animals were fed a standard
laboratory diet and tap water ad libitum and kept at 23 ± 1 C with
a 12-h light/dark cycle, light at 7 AM. A total of 5–6 rats per group
were tested. All experiments were carried out in accordance with
the European Communities Council Directive of 24 November
1986 (86/609/EEC) for experimental animal care. All efforts were
made to minimise the number of animals used and their suffering.
2.4. Methods
2.4.1. Isolation of SalB
The isolation procedure was carried out according to the
literature (Wang et al., 2007), slightly modified. The dried roots
of S. miltiorrhiza Bunge were ground to powder and extracted three
times with 2 l of 80% aqueous ethanol. The extract was filtered and
the filtrate was concentrated in a rotavapor to eliminate ethanol
and subsequently extracted with n-hexane (500 ml, three times),
in order to remove completely the lipophilic constituents,
tanshinones. The aqueous phase was then partitioned with
dichloromethane (300 ml, twice) to remove non polar constituents,
and successively acidified to a final pH 2 (10% hydrochloric acid)
and re-extracted with ethyl acetate (300 ml, three times). The
organic phase concentrated to give a residue of approximately
12.5 g. Part of the extract (2 g) was redissolved in 50% MeOH
and subjected to column chromatography over Sephadex LH-20
(Amersham Biosciences AB, Uppsala, Sweden) using EtOH 20%, to
give a salvianolic B enriched fraction. Repeated chromatographic
separations of this fraction over Sephadex LH-20 columns using
the same elution system afforded pure SalB. All fractionations were
monitored by TLC and HPLC-UV-DAD. TLC analyses were carried
out on silica gel 60 plates (F254, Merck, Darmstadt Germany) using
the solvent system ethylacetate:CH3COOH:H2O 90:5:5) and
vanillin reagent (5% vanillin in MeOH:5% H2SO4 in EtOH, 1:1).
Purity of isolated SalB (96%) was assessed by 1H NMR analysis
and HPLC-DAD–ESI-MS analysis using SalB reference standard
(purity >98.5% by HPLC-DAD–ESI-MS, GC, NMR).
2.4.2. Analytical HPLC-DAD characterisation
The HPLC system consisted of a HP 1100 L instrument with a
Diode Array Detector and managed by a HP 9000 workstation
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Phenomenex Luna RP C18 (150 mm  3 mm i.d., 5 lm) maintained
at 26 C. The eluents were H2O at pH 3.2 by formic acid (A) and
acetonitrile (B). Two different linear gradients were applied. Linear
gradient (1) was used for the monitoring of the fractionation and
evaluation of purity of SalB. The following multi-step linear gradi-
ent was applied: from 90% A to 85% A in 10 min, in 7 min to 22% B,
with a plateaux of 8 min; 2 min to 25% and then 13 min to 66% of B.
Total time of analysis was 40 min, equilibration time was 10 min,
flow rate was 0.4 ml min1, injection volume was 2 ll and oven
temperature 26 C. The UV–Vis spectra were recorded between
220 and 500 nm and the chromatographic profiles were registered
at 254, 290, 330 and 350 nm. Linear gradient (2) was used for the
calculation of SalB in plasma. The following multi-step linear
gradient was applied: from 85% A to 70% A in 10 min, from 70%
A to 48% A in 13 min and then 5 min to 85% of A. Total time of
analysis was 28 min, equilibration time was 5 min, flow rate was
0.4 ml min1, injection volume was 2 ll and oven temperature
26 C. The UV–Vis spectra were recorded between 220 and
500 nm and the chromatographic profiles were registered at 254,
290, 330 and 350 nm.
2.4.3. Analytical HPLC–ESI-MS
The HPLC system described above was interfaced with a HP
1100 MSD API-electrospray (Agilent Technologies, Palo Alto, CA,
USA). The interface geometry, with an orthogonal position of the
nebuliser with respect to the capillary inlet, allowed use of
analytical conditions similar to those used for HPLC-DAD analysis
in order to achieve the maximum sensitivity of ESI values. The
same column, time period and flow rate were used during the
HPLC–ESI-MS analyses. Mass spectrometry operating conditions
were optimised in order to achieve maximum sensitivity values:
negative and positive ionisation mode, scan spectra from m/Z
100 to 800, was used with a gas temperature of 350 C, nitrogen
flow rate of 10 l min1, nebuliser pressure 30 psi, quadrupole
temperature 30 C, capillary voltage 3500 V. The applied fragmen-
tors were in the range 80–180 V. Identification of constituents was
carried out by HPLC-DAD and HPLC–ESI-MS analyses, and/or by
comparison and combination of their retention times, UV–Vis
and mass spectra of the peaks with those of authentic standards
when possible, or isolated compounds or characterised extracts
as well as based on literature data.
2.4.4. Linearity, LOD, LOQ, precision
The linearity range of responses of the standard SalB in MeOH
and SalB in plasma was determined on five concentration levels
with three injections for each level. Calibration graphs for HPLC
were recorded with sample amounts ranging from 6.6  103 to
3.3 lg (SalB in MeOH) and from 57.2  103 to 0.86 lg (SalB in
plasma): stock solutions of the standards (LOQ included) were
prepared at different concentrations ranging from 3.3  103 to
0.33 mg/ml (SalB in MeOH) and from 28.6  103 to 0.286 mg/ml
(SalB in plasma) and injected into HPLC (injection volumes varying
from 2 to 10 ll). The limit of detection (LOD) and quantification
(LOQ) under the chromatographic conditions were determined by
injecting a series of the standard solutions until the signal-to-noise
(S/N) ratio for each compound was 3 for LOD and 10 for LOQ. For
the intra-day variability test, freshly prepared standard samples
(SalB in MeOH and SalB in plasma) in the range of the calibration
curve were analysed in six replicates within 1 day. For the inter-
day variability test, the standard solutions, the isotonic saline
solutions and the liposomal formulations were examined in
triplicates for three consecutive days. The contents of SalB in each
case were evaluated by HPLC-DAD (for SalB in MeOH or in isotonic
saline solution) and HPLC–ESI-MS (for SalB in plasma) to calculate
the relative standard deviation (%RSD).2.4.5. Production of conventional and PEGylated SalB-loaded
liposomes
Conventional and PEGylated SalB-loaded liposomes (SalB-CL
and SalB-PL respectively) were prepared according to the film
hydration method (Bangham et al., 1965). Conventional liposomes
were prepared using P90G, cholesterol and SalB and optimised
using the OVAT technique (One-Variable-at-a-Time). P90G and
cholesterol were firstly dissolved in dichloromethane and the
organic solvent was evaporated under vacuum. The dry lipid film
was hydrated by the addition of SalB physiological solution (NaCl
0.9% w/v). The dispersion was stirred with a mechanical stirrer
for 30 min in a water-bath at the constant temperature of 38 C.
In order to reduce the dimensions of the vesicles from MLVs to
LUVs, a high pressure homogenizer Emulsiflex C3 (AVESTIN
Europe GmbH, Mannheim, Germany) was used at the applied pres-
sure of 150,000 kPa for 60 s. Alternatively, vesicle dimensions were
reduced and their homogeneity was increased by the extrusion
technique. Liposomes were extruded 21-times through poly-
carbonate filters with pore size 400, 200 and 100 nm sequentially
using a Liposofast basic (AVESTIN Europe GmbH, Mannheim,
Germany). Also the PEGylated liposomes containing 18:0/18:0
PEG2000, P90G, cholesterol and SalB were optimised using the
OVAT technique. 18:0/18:0 PEG 2000 was weighted together
with P90G and cholesterol and dissolved in dichloromethane using
the same method preparation as described for conventional
liposomes.
2.4.6. Particle characterisation of liposomes
Particle size was measured by a Dynamic Light Scattering (DLS),
Zetasizer Nano series ZS90 (Malvern Instruments, Malvern, UK)
equipped with a JDS Uniphase 22 mW He–Ne laser operating at
632.8 nm, an optical fiber-based detector, a digital LV/LSE-5003
correlator and a temperature controller (Julabo water-bath) set at
25 C. Time correlation functions were analysed to obtain the
hydrodynamic diameter of the particles (Zh) and the particle size
distribution (polydispersity index, PDI) using the ALV-60X0
software V.3.X provided by Malvern. Autocorrelation functions
were analysed by the cumulants method (fitting a single
exponential to the correlation function to obtain the mean size
(Zave) and polydispersity index (PDI) or by CONTIN (fitting a
multiple exponential to the correlation function to obtain particle
size distributions). Scattering was measured in an optical quality
4 ml borosilicate cell at a 90 angle, diluting the different samples
100-folds in physiological solution NaCl 0.9% w/v.
2.4.7. Electrophoretic mobility
Zeta potentials (f-potentials) of the liposome systems were
measured using the Malvern Instruments Zetasizer Nano series
ZS90. For all samples, an average of three measurements at a
stationary level was taken. The cell used was a 5  2 mm
rectangular quartz capillary. The temperature was kept constant
at 25 C by a Haake temperature controller. The zeta potential
was calculated from the electrophoretic mobility, lE, using the
Henry correction to Smoluchowski’s equation.
2.4.8. Transmission electron microscopy
Liposome dispersions were analysed by TEM analysis with the
negative stain technique in terms of morphology and mean
diameter. A drop (10 ll) of vesicle dispersion diluted 10-times
was applied to a carbon film-covered copper grid. Most of the
dispersion was blotted from the grid with filter paper to form a
thin film specimen, which was stained with a phosphotungstic acid
solution 1% w/v in sterile water. The samples were dried for 3 min
and then were examined under a JEOL 1010 electron microscope
and photographed at an accelerating voltage of 64 kV.
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Free SalB was removed from the surface of liposomes by gel
permeation chromatography on Sephadex G-50. Liposomal
dispersion (200 ll) was loaded in a minicolumn containing a dry
matrix (G-50 gel bed). The not entrapped material was removed
by centrifugation at 1000g for 3 min at a controlled temperature
(+4 C). Purified liposomes were collected and were disrupted
using the dilution method with an organic solvent, then were
submitted to ultrasonication in a bath for 30 min. After centrifuga-
tion at 12,000 rpm for 5 min, the content of encapsulated SalB in
liposomes was quantified by HPLC–ESI-MS analysis, using SalB as
external standards. The entrapment efficiency (EE) is reported as
the percentage of SalB entrapped in the vesicles: EE (%) = {(amount
of SalB entrapped in the vesicles)/(total amount of SalB used in the
preparation)}  100.
2.4.10. Stability studies
Stability both of SalB isotonic saline solutions used in the in vivo
tests as well as liposomal formulations containing SalB at the
concentration of 20 mg/ml was assessed during one week using
the developed HPLC-DAD analytical method.
2.4.11. In vivo experiments
2.4.11.1. Application of test substances. Drugs were dissolved in
isotonic (NaCl 0.9% w/v) saline solution or dispersed in carboxy-
methylcellulose sodium 1% solution immediately before use. Drug
concentrations were prepared so that the necessary dose could be
administered in a volume of 10 ml kg1 by i.p. injection.
2.4.11.2. Chronic constriction injury (CCI). A peripheral mono
neuropathy was produced in adult rats by placing loosely
constrictive ligatures around the common sciatic nerve according
to the method described by Bennett and Xie (1988). Rats were
anaesthetised with chloral hydrate. The common sciatic nerve
was exposed at the level of the middle of the thigh by blunt dissec-
tion through biceps femoris. Proximal to sciatica’s trifurcation,
about 1 cm of the nerve was freed of the adhering tissue and four
ligatures (3/0 silk tread) were tied loosely around it with about
1 mm spacing. The length of the nerve thus affected was 4–5 mm
long. Great care was taken to tie the ligatures such that the
diameter of the nerve was seen to be just barely constricted when
viewed with 40 magnification. In every animal, an identical dis-
section was performed on the opposite side except that the sciatic
nerve was not ligated. The left paw was untouched.
2.4.11.3. Paw-pressure test. The instrument exerts a force which is
applied at a constant rate (32 g/s) with a cone-shaped pusher on
the upper surface of the rat hind paw. The force is continuously
monitored by a pointer moving along a linear scale. The pain
threshold is given by the force which induces the first struggling
from the rat. An arbitrary cut off value of 250 g was adopted. Those
mice scoring less than 40 g or over 75 g in the pretest were rejected
(25%). The pain threshold was measured before (pretest) and 15, 30
and 45 min after the beginning of the test.
2.4.11.4. Plasmatic concentration of SalB. Fifteen male Sprague–
Dawley albino rats (180–200 g) were randomly separated into
three groups. One group received free SalB dissolved in
physiological solution NaCl 0.9% w/v at the dosage of 100 mg/kg
intraperitoneally, and the other two groups were given SalB-loaded
conventional liposomes (SalB-CL) and SalB-loaded PEGylated lipo-
somes (SalB-PL) at the same dosage of SalB. Blood sampleswere col-
lected from the tail vein into heparinised tubes (Multivette,
Sarsted, Italy) corresponding to the maximum of antihyperalgesic
activity in each case: 15 min after administration, in the case of free
SalB as well as SalB-CL, and 30 min after administration in the caseof SalB-PL. Blood samples were immediately centrifuged at
2000 rpm for 20 min at 17 C to separate plasma from other blood
elements. The obtained plasma was stored at 80 C prior to anal-
ysis. A pre-treatment procedure is often needed to remove blood
protein and potential interferences prior to HPLC-DAD–ESI-
MS analysis. Protein precipitation is commonly used for fast sample
clean-up and disrupting of protein–drug binding. A calibration
curve (r2 = 0.9999) was determined by the constant volume of
blank rat plasma with increasing concentration of SalB (ranging
from 0 to 100 lM as the final concentration of SalB). Each sample,
including each point of the calibration curve, was diluted seven
times with acetonitrile in order to precipitate plasma proteins.
Samples were vortexed for 15 s and centrifuged at 10,000 rpm for
2.5 min. Each sample (200 ll) was transferred in micro-vials.
2.4.11.5. Statistics. All experimental results are given as the
mean ± SEM. An analysis of variance ANOVA, followed by Fisher’s
Protected Least Significant Difference procedure for post hoc com-
parison, were used to verify significance between two means. Data
were analysed with the StatView software for the Macintosh.
p values of less than 0.05 were considered significant.3. Results and discussion
3.1. Isolation of SalB
A simple and fast isolation method was set up: the dried crude
hydro-alcoholic extract of Danshen was firstly submitted to liquid–
liquid extraction obtaining an extract deprived from tanshinones
and other lipophilic constituents present in the plant.
Then Sephadex LH-20 using hydro-alcoholic solutions was used
for a rapid separation and refinement of SalB, taking advantage of
the difference in the molecular size of SalB (tetramer) compared to
other monomers, dimers and trimers of caffeic acid present in the
extract. The combination of both techniques represented a safe and
convenient separation scheme yielding almost pure SalB (96%). The
presence of SalB in the extract was assessed by a comparison of its
tR with the authentic sample SalB international standard and it was
confirmed by UV and NMR data.
3.2. Linearity, LOD, LOQ, precision
All calibration curves showed good linearity. The following r2
values were obtained: SalB r2 = 0.9996 (regression curve: y =
0.0004x  0.0591); SalB in plasma r2 = 0.9999 (regression curve:
y = 1.598  107  0.0341).
LOD for SalB was 1.89 ng (0.94 lg/ml, 2 ll of injection) and LOQ
was 6.6 ng (3.3 lg/ml, 2 ll of injection). For SalB in plasma, LOD
was calculated as 28.6 ng (5.72 lg/ml, 5 ll of injection) and
LOQ was 57.2 ng (28.6 lg/ml, 2 ll of injection).
The overall intra- and inter-day time variations of the standards
were less than 10.64% and 2.34% for SalB and less than 2.13% and
3.44% for SalB in plasma, respectively.
In addition, the amount of SalB in isotonic saline solutions
remained stable (not less than 93% residual percentage) during
the three days of inter-day variability tests.
3.3. Anti-hyperalgesic activity of SalB
The antihyperalgesic activity of pure SalB was investigated in an
animal model of neuropathic pain (CCI). Paw withdrawal threshold
was measured using Randall and Selitto apparatus exerting a force
that increases at a constant rate (32 g/s). Stimulus at which rats
withdrew the paw was recorded before treatment and after drug
administration at different times (15, 30, 45 and 60 min). The
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expressed as grams. The positive controls used as reference
compounds are reported in Fig. 2.
SalB was effective against mechanical hyperalgesia when
intraperitoneally administered. Several dosages of pure SalB,
dissolved in physiological solution, were tested and the dose–
response curve was assessed to find the lowest active dosage. SalB
reverted the mechanical hyperalgesia, evaluated in the paw-
pressure test, in CCI rats when administered at the dose of
100 mg/kg, 15 min after administration (41.1 ± 1.3 vs. 60.3 ± 2.9,
p < 0.05) (Fig. 3). The dose of 300 mg/kg resulted to be less activePa
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Fig. 2. Positive controls used as reference compounds in a chronic constriction
injury of the sciatic nerve (CCI) in the rat paw-pressure test.
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Fig. 3. SalB intraperitoneal administration in a chronic constriction injury of the
sciatic nerve (CCI) in the rat paw-pressure test.than 100 mg/kg and we might hypothesise the presence of a
bell-shaped trend, common feature with natural compounds.
No advantages occurred when administering SalB intraperito-
neally for a 7 days period (prolonged administration): hyperalgesia
was reverted only in correspondence to a single time point for each
dosage. At the dosage of 100 mg/kg, SalB was active with a value
statistically acceptable only 15 min after administration (38.6 ±
2.8 vs. 58.4 ± 3.6, p < 0.05) and at the dosage of 30 mg/kg with a
value statistically acceptable only 30 min after administration
(34.9 ± 0.8 vs. 54.6 ± 4.4, p < 0.05) (Fig. 4).
The safety of SalB was also assessed: it did not modify animals’
gross behaviour at the highest effective doses. The Rota-rod test
was employed to reveal any alterations of the motor coordination
induced by the investigated compound. The number of falls from
the rotating rod showed the lack of any impairment in the motor
coordination of animals treated with SalB in comparison to the
untreated group, ruling out that the results obtained were due to
animals’ altered viability (data not shown).3.4. Preparation and characterisation of liposomes
Liposomes were prepared using different ratios of phospholip-
ids, cholesterol and 18:0/18:0 PEG2000, in order to optimise the
formulation in terms of size and encapsulation efficacy. The molar
ratio between the constituents of the conventional liposomes
P90G:cholesterol:SalB were optimised as 2.5:0.5:2.3 using the
OVAT technique. The molar ratio between the constituents of the
PEGylated liposomes 18:0/18:0 PEG2000, P90G, cholesterol and
SalB were optimised as 0.125:2.5:0.5:2.3, using the OVAT as well.
The main parameters typically described for summarising the
properties of the tested formulation are reported in Table 1.
Briefly, the particle sizes of various liposomes were around
200 nm in the case of SalB-CL and around 150 nm in the case of*P<0.05 vs pretest dx
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Fig. 4. SalB intraperitoneal administration for 7 days (prolonged administration) in
a chronic constriction injury of the sciatic nerve (CCI) in the rat paw-pressure test.
Table 1
Size, polydispersity index (PDI), f-potential and encapsulation efficacy (EE%) of SalB-
loaded conventional (SalB-CL) and PEGylated liposomes (SalB-PL). Data are shown as
mean of three samples (±SD).
Mean diameter
(nm)
PDI f-Potential
(mV)
EE (%)
SalB-CL 206.8 ± 7.3 0.29 ± 0.01 11.6 ± 1.84 24.84 ± 0.28
SalB-PL 140.0 ± 6.5 0.23 ± 0.01 7.88 ± 0.52 22.72 ± 0.88
*P<0.05 vs pretest dx
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Fig. 7. SalB-loaded liposomes intraperitoneal administration in a chronic constric-
tion injury of the sciatic nerve (CCI) in the rat paw-pressure test.
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distribution: PDI < 0.3 and PDI  0.2 for SalB-Cl and SalB-PL,
respectively. In order to reduce the dimensions of the vesicles from
MLVs to LUVs, a high pressure homogenizer Emulsiflex C3 and an
Extruder were used alternatively. The size and the polydispersity
index of the samples obtained by these two optimised techniques
were comparable. As expected, conventional liposomes are nega-
tively charged (f-potential is around 12 mV), while the presence
of PEG to the liposomal surface provides more efficient charge
neutralisation (f-potential were halved).
The drug loading efficiencies were similar for both conventional
and PEGylated liposomes after evaluation by HPLC-DAD analysis.
The chemical stability of SalB into the vesicles is maintained
constant (not less than 95% residual percentage) at least during
the three days of inter-day variability tests. The transmission
electron micrograph by negative stain (Figs. 5 and 6) provided
important details on the morphology and the dimension of the
vesicles. Liposomes were large unilamellar vesicles, sphere-shaped
and with a size comparable with the results from DLS analysis. In
particular, the SalB-PL showed the emblematic conformational
cloud forming by PEG chains (Fig. 6).3.5. In vivo studies of liposomes
SalB-loaded conventional and PEGylated liposomes were
tested in the Paw pressure test and compared with the
performance of the free drug (Fig. 7). Both for free SalB andFig. 5. SalB-loaded conventional liposomes. LUV: large unilamellar vesicles. Trans-
mission electron micrograph by negative stain.
Fig. 6. SalB-loaded PEGylated liposomes. LUV: large unilamellar vesicles. Trans-
mission electron micrograph by negative stain.SalB-loaded conventional liposomes, administered at the active
dosage of 100 mg/kg i.p., the antihyperalgesic effect started
15 min after administration (39.2 ± 2.2 vs. 59.3 ± 2.4, p < 0.05). On
the other hand, SalB-loaded PEGylated liposomes shifted the maxi-
mum of antihyperalgesic activity 30 min after administration
(50.9 ± 3.8 vs. 58.5 ± 2.7, p < 0.05) and the effect was still significant
at 45 min (40.3 ± 3.7 vs. 58.2 ± 2.1, p < 0.05). This means that only
PEGylated formulation ameliorates the performance of the drug
by delaying, increasing and prolonging in time its antihyperalgesic
effect.3.6. Plasmatic concentration of SalB
In order to strengthen the above pharmacological results, the
plasmatic concentrations of SalB in rats were quantified. The blood
samples were collected corresponding to the maximum of
antihyperalgesic activity in each case: 15 min after administration
in the case of free SalB as well as SalB-CL and 30 min after adminis-
tration in the case of SalB-PL. The three groups of rats received SalB
dissolved in physiological solution NaCl 0.9% w/v, SalB-CL and
SalB-PL respectively at the samedosage of 100 mg/kg intraperitone-
ally. The SalB plasmatic concentrations were quantified by HPLC-
DAD–ESI-MS analysis, in modality scan and negative fragmentor,
monitoring the pseudomolecular ion (717 m/Z). Plasmatic SalB
values reported in Table 2, supported the fact that free or drug
vehiculated in conventional liposomes had the same blood concen-
trations at the maximum time of antihyperalgesia, in good
agreement with the results obtained in the Paw pressure test
having a similar in vivo efficacy.
Conversely, SalB-loaded PEGylated liposomes showed a plas-
matic concentration more higher than 4-fold in comparison with
the other formulations and indeed the in vivo efficacy was also
increased.Table 2
Mean SalB plasma concentration in the correspondence of the maximum of anti-
hyperalgesic activity of free SalB, conventional (SalB-CL) and PEGylated (SalB-PL)
SalB-loaded liposomes following i.p. administration at the dosage of 100 mg/kg.
Values were expressed as mean ± SD (n = 4).
Plasmatic concentration (lM) Time (min)
SalB 95 ± 1.7 15
SalB-CL 80 ± 2.0 15
SalB-PL 388 ± 1.3 30
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A fast, simple and efficient separation protocol was developed
for the purification and isolation of SalB from a crude hydro-
alcoholic extract of Danshen; it excludes the use of successive
column chromatographies on silica gel and applies instead
Liquid–Liquid Extraction and Size Exclusion Chromatography. Both
methodologies have distinct advantages for the majority of the
natural products: (i) they eliminate irreversible adsorptive loss,
(ii) limit the creation of artefacts, (iii) low solvent consumption
and (iv) are fast methods and could be easily scaled up at the
industrial level.
The anti-hyperalgesic activity of SalB was assessed in an animal
model of neuropathic pain (CCI) and to the best of our knowledge,
this is the first report. Due to the poor low bioavailability of SalB,
conventional and PEGylated liposomes were developed as suitable
drug carriers. After optimisation of the vesicles features in terms of
particle size, polydispersity index, encapsulation efficacy and
morphology, liposomes were administered intraperitoneally to
evaluated their antihyperalgesic activity and compare their
performance with that of free drug. Drug encapsulation into
PEGylated liposomes increased and prolonged the antihyperalgesic
activity of SalB. The different in vivo performance of conventional
and PEGylated liposomes was expected as recently reported in
another study by the same authors (Isacchi et al., 2011). It could
be related to the incorporation of PEG in the liposomes surface
which can modify the pharmacokinetic profile of SalB, its metabo-
lism and/or the plasma protein binding. These effects of the PEGy-
lated liposomes were also supported by a preliminary evaluation of
plasmatic concentration of SalB which resulted more than 4-fold in
comparison with the other formulations taken at the maximum of
the efficacy.
These studies represent the starting point for further and
supplementary investigations to understand the potential
application in the therapy of SalB-loaded PEGylated liposomes in
the treatment of neuropathic pain.References
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